Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

1. Age ≥ 18.

2. Subjects with histopathologically and/or flow cytometry-confirmed diseases accordingto the 2016 World Health Organization (WHO) classification criteria forlymphohematopoietic neoplasms or meeting the International Workshop on ChronicLymphocytic Leukemia (iwCLL) criteria: relapsed or refractory CLL/SLL, relapsed orrefractory MCL. Patients must have received at least two prior lines of adequatesystemic therapy before study entry, and at least one prior systemic therapy shouldinclude Bruton's kinase inhibitor (BTKi).

3. For subjects with R/R MCL: Patients must have measurable disease per the Lugano 2014criteria.

4. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS)score of ≤ 1 and a life expectancy of ≥ 6 months.

5. Adequate hematologic, hepatic, renal, pulmonary and cardiac function

6. Patients with basically normal coagulation function

7. Patients with fertility potential and their partners need contraception

8. Subjects can communicate with the investigator well and to complete the study asspecified in the study.

Exclusion Criteria:

1. Known central nervous system involvement by lymphoma/leukemia.

2. Known or suspected history of Richter's transformation.

3. Prior autologous stem cell transplant (unless ≥ 3 months since transplant); or priorchimeric cell therapy (unless ≥ 3 months since cell infusion).

4. A history of allogeneic stem cell transplantation.

5. An interval of less than 5 half-lives from the last dose of a strong CYP3A or CYP2C8inhibitor or inducer (chemical agent, herbal medicine and dietary supplement) to thefirst dose of the investigational product, or a plan to use concurrentlymedications, dietary supplements or food (e.g., grapefruit or grapefruit juice) withstrong CYP3A or CYP2C8 inhibitory or inductive effect during study participation

6. Presence of active infection that currently requires intravenous systemicanti-infective therapy.

7. History of immunodeficiency, including a positive human immunodeficiency virus (HIV)antibody test.

8. History of significant cardiovascular disease

9. Patients with previous or concomitant central nervous system disorders

10. Grade 2 or above toxicity due to prior anti-cancer therapy at screening

11. Known alcohol or drug dependence

12. Unable to swallow tablets or presence of disease significantly affectinggastrointestinal function such as malabsorption syndrome, resection of the stomachor small bowel, bariatric surgery procedures, symptomatic inflammatory boweldisease, or partial or complete bowel obstruction.